XOMA Royalty Corporation
XOMA Royalty Corporation operates as a biotech royalty aggregator in the US and Asia Pacific. It has a portfolio of economic rights to milestone and royalty payments from partnered therapeutics. The company also focuses on early-stage clinical assets with commercial sales potential licensed to partners. Additionally, it acquires late-stage clinical or commercial asset revenue streams.
Overview
Strengths
- Valued below its Biotechnology peers: P/E 15.0x vs. a median of 20.4x.
- EBITDA margin of 100.0% beats 99% of its 128 Biotechnology peers (median 0.0%).
- Cheaper than its own history: P/E 15.0x vs. a historical average of 63.0x.
- Paying down debt: long-term debt fell by 12.9 percentage points of total assets last year.
Weaknesses
- Unreliable cash generation: free cash flow was negative in 5 of the last 6 years.
- Our discounted cash flow target price (7.36 USD) is 82% below the current price.
- Unstable profitability: operating margin ranged from -493% to 98% over the last 6 years, with operating losses in 3 of them.
- Earnings quality red flag: reported profit exceeds operating cash flow by 10.6% of total assets.
- Valued at a premium to its Biotechnology peers: EV/EBITDA 25.9x vs. a median of 15.0x.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data